LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Kodu・Aktsiate loetelu・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Suletud

SektorTervishoid

4.26 -4.27

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.25

Max

4.39

Põhinäitajad
By Trading Economics
Sissetulek	9.6M -162M
Müük	-14M 5.2M
Aktsiakasum	-0.36
Kasumimarginaal	-3,135.324
Töötajad	800
EBITDA	6.4M -141M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+74.55% upside

Turustatistika
By TradingEconomics
Turukapital	-186M 2.2B
Eelmine avamishind	8.53
Eelmine sulgemishind	4.26

Uudiste sentiment

By Acuity

50%

153 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

4.15 / 4.75 Toetus ja vastupanu

Recursion Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. dets 2025, 17:29 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19. dets 2025, 16:47 UTC

Suurimad hinnamuutused turgudel

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19. dets 2025, 16:10 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

20. dets 2025, 19:00 UTC

Tulu

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

19. dets 2025, 22:33 UTC

Tulu

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19. dets 2025, 22:19 UTC

Tulu

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19. dets 2025, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 21:44 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. dets 2025, 21:38 UTC

Tulu

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19. dets 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19. dets 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19. dets 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19. dets 2025, 18:00 UTC

Market Talk

Tulu

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19. dets 2025, 17:41 UTC

Tulu

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19. dets 2025, 17:24 UTC

Market Talk

Tulu

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19. dets 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

19. dets 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19. dets 2025, 16:29 UTC

Tulu

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19. dets 2025, 16:20 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19. dets 2025, 16:19 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19. dets 2025, 16:18 UTC

Omandamised, ülevõtmised, äriostud

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19. dets 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. dets 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19. dets 2025, 16:05 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 16:04 UTC

Omandamised, ülevõtmised, äriostud

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19. dets 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19. dets 2025, 15:21 UTC

Market Talk

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19. dets 2025, 15:09 UTC

Market Talk

Gold Flat But Set for Weekly Gains -- Market Talk

19. dets 2025, 15:09 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Recursion Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

74.55% tõus

12 kuu keskmine prognoos

Keskmine 7.75 USD 74.55%

Kõrge 11 USD

Madal 5 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Recursion Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Recursion Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.15 / 4.75Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

153 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.